AU2008323947B2 - Extracellular histones as biomarkers for prognosis and molecular targets for therapy - Google Patents

Extracellular histones as biomarkers for prognosis and molecular targets for therapy Download PDF

Info

Publication number
AU2008323947B2
AU2008323947B2 AU2008323947A AU2008323947A AU2008323947B2 AU 2008323947 B2 AU2008323947 B2 AU 2008323947B2 AU 2008323947 A AU2008323947 A AU 2008323947A AU 2008323947 A AU2008323947 A AU 2008323947A AU 2008323947 B2 AU2008323947 B2 AU 2008323947B2
Authority
AU
Australia
Prior art keywords
histone
inhibitor
peptide
subject
cytotoxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008323947A
Other languages
English (en)
Other versions
AU2008323947A1 (en
Inventor
Charles T. Esmon
Jun Xu
Xiaomei Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of AU2008323947A1 publication Critical patent/AU2008323947A1/en
Application granted granted Critical
Publication of AU2008323947B2 publication Critical patent/AU2008323947B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
AU2008323947A 2007-11-06 2008-11-06 Extracellular histones as biomarkers for prognosis and molecular targets for therapy Active AU2008323947B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98588607P 2007-11-06 2007-11-06
US60/985,886 2007-11-06
PCT/US2008/082632 WO2009061918A1 (en) 2007-11-06 2008-11-06 Extracellular histones as biomarkers for prognosis and molecular targets for therapy

Publications (2)

Publication Number Publication Date
AU2008323947A1 AU2008323947A1 (en) 2009-05-14
AU2008323947B2 true AU2008323947B2 (en) 2014-02-20

Family

ID=40270490

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008323947A Active AU2008323947B2 (en) 2007-11-06 2008-11-06 Extracellular histones as biomarkers for prognosis and molecular targets for therapy

Country Status (6)

Country Link
US (5) US8716218B2 (enExample)
EP (1) EP2209485B1 (enExample)
JP (1) JP2011503012A (enExample)
AU (1) AU2008323947B2 (enExample)
CA (1) CA2704974C (enExample)
WO (1) WO2009061918A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2209485B1 (en) 2007-11-06 2016-03-30 Oklahoma Medical Research Foundation Extracellular histones as biomarkers for prognosis and molecular targets for therapy
US20100292131A1 (en) * 2007-11-16 2010-11-18 Pronota N.V. Biomarkers and methods for diagnosing, predicting and/or prognosing sepsis and uses thereof
JP5960596B2 (ja) 2010-08-20 2016-08-02 学校法人 城西大学 免疫抑制活性を有するモノクローナル抗体またはその抗原結合断片
JPWO2012067152A1 (ja) * 2010-11-16 2014-05-12 三菱化学株式会社 ＥｎｄｏｔｈｅｌｉａｌＰｒｏｔｅｉｎＣＲｅｃｅｐｔｏｒ蛋白質による脳梗塞の検査方法
DK2646037T3 (en) * 2010-12-01 2019-03-04 Univ Australian National use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis
TWI442934B (zh) * 2011-03-11 2014-07-01 Univ Taipei Medical 組蛋白h4抗體的用途
JP2015117181A (ja) * 2012-02-22 2015-06-25 学校法人 城西大学 敗血症治療剤
CN104994875B (zh) * 2013-02-15 2018-10-09 免疫医疗公司 嵌合和人源化抗组蛋白抗体
JPWO2013125687A1 (ja) * 2013-02-22 2015-07-30 学校法人 城西大学 炎症疾患治療剤
FR3007411B1 (fr) * 2013-06-21 2015-07-03 Agronomique Inst Nat Rech Anticorps monocatenaire a chaine lourde de camelide dirige contre la chromatine et utilisations
US10351621B2 (en) 2014-06-24 2019-07-16 Immunomedics, Inc. Anti-histone therapy in acute kidney injury
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
JP6994939B2 (ja) * 2014-07-02 2022-02-04 インフレクティス・バイオサイエンス プロテオパチーの処置のためのベンジリデングアニジン誘導体の新規な治療的使用
US10633410B2 (en) 2014-12-22 2020-04-28 University Of Iowa Research Foundation Nucleic acid aptamers to treat histone-induced disease states
EP3256858B1 (en) 2015-02-10 2020-03-25 B.R.A.H.M.S GmbH Histone h4 peptide as a biomarker
CN106611094B (zh) * 2015-10-15 2021-08-06 北京寻因生物科技有限公司 基于肠道微生物菌群预测及干预化疗药物毒副反应的系统
JP6738652B2 (ja) * 2016-05-26 2020-08-12 シスメックス株式会社 試料分析方法、試料分析装置および試薬
WO2018029213A1 (en) 2016-08-09 2018-02-15 B.R.A.H.M.S Gmbh Histones and/or proadm as markers indicating organ dysfunction
CA3033094A1 (en) 2016-08-09 2018-02-15 B.R.A.H.M.S Gmbh Histones and/or proadm as markers indicating an adverse event
CN106397575A (zh) * 2016-10-20 2017-02-15 上海懿贝瑞生物医药科技有限公司 一种具有胞外组蛋白毒性抑制作用的多肽制备方法及用途
US11740245B2 (en) 2016-11-04 2023-08-29 Centro De Investigación Biomédica En Red (Ciber-Isciii) Mass spectrometry-based methods for the detection of circulating histones H3 and H2B in plasma from sepsis or septic shock (SS) patients
CA3052349C (en) 2017-02-02 2024-06-04 B.R.A.H.M.S Gmbh Proadm as marker indicating an adverse event
JP2020073459A (ja) * 2017-03-06 2020-05-14 学校法人順天堂 ヒストンによる細胞傷害を抑制するための薬剤
ES2913665T3 (es) 2017-09-18 2022-06-03 Santersus Ag Método y dispositivo para la purificación de sangre a partir de ADN celular libre en circulación
GB201804833D0 (en) * 2018-03-26 2018-05-09 Univ Liverpool Pro-coagulant histones
CN110101838B (zh) * 2019-04-29 2022-07-01 陕西师范大学 一种提高组蛋白抗大肠杆菌性能的方法
CN111202839A (zh) * 2020-02-21 2020-05-29 佛山科学技术学院 一种组蛋白h4在抑制禽流感病毒中的应用
CA3174032A1 (en) * 2020-04-03 2021-10-07 Francois Rieger Use of an arsenic compound for treating a short or long cytokine storm in various autoimmune/inflammatory diseases in humans or animals
CN112679579B (zh) * 2020-12-29 2022-02-01 潍坊医学院 一种分离自华蟾素注射液的镇痛肽ci5及其应用
WO2023126672A1 (en) 2021-12-27 2023-07-06 Santersus Ag Method and device for removal of circulating cell free dna

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1544214A1 (en) * 2002-07-22 2005-06-22 Chugai Seiyaku Kabushiki Kaisha Non-neutralizing anti-apc antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4676500A (en) * 1999-04-28 2000-11-10 Northwestern University Localization of major peptide autoepitopes for nucleosome specific t cells of systemic lupus erythematosus
US7238656B2 (en) * 2001-08-29 2007-07-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Protective factors against inflammation, burns and noxious stimuli
US7528227B2 (en) * 2004-03-23 2009-05-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone H2A peptide derivatives and uses thereof
JP4834826B2 (ja) 2003-07-22 2011-12-14 独立行政法人産業技術総合研究所 ヒストンｈ３及びｈ４リンカー領域を認識するモノクローナル抗体及びその産生ハイブリドーマ
SG188175A1 (en) * 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
JP2007246473A (ja) 2006-03-17 2007-09-27 Chemo Sero Therapeut Res Inst 臓器障害抑制剤
EP2011490A1 (en) 2007-07-05 2009-01-07 Sanofi-Aventis Beta adrenergic receptor ligand derivatives for modulating apoptosis
EP2209485B1 (en) * 2007-11-06 2016-03-30 Oklahoma Medical Research Foundation Extracellular histones as biomarkers for prognosis and molecular targets for therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1544214A1 (en) * 2002-07-22 2005-06-22 Chugai Seiyaku Kabushiki Kaisha Non-neutralizing anti-apc antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ABAKUSHIN D. et al, Histones Evoke Thymocyte Death in vitro; Histone-Binding Immunoglobulins Decrease Their Cytotoxicity, BIOCHEMISTRY (Moscow), 1999, Vol. 64(6), Pg. 693-698 *

Also Published As

Publication number Publication date
US20090117099A1 (en) 2009-05-07
US20150344556A1 (en) 2015-12-03
EP2209485A1 (en) 2010-07-28
EP2209485B1 (en) 2016-03-30
US10350261B2 (en) 2019-07-16
AU2008323947A1 (en) 2009-05-14
JP2011503012A (ja) 2011-01-27
US20190216884A1 (en) 2019-07-18
CA2704974A1 (en) 2009-05-14
CA2704974C (en) 2019-06-04
US8716218B2 (en) 2014-05-06
US10238711B2 (en) 2019-03-26
WO2009061918A1 (en) 2009-05-14
US11458187B2 (en) 2022-10-04
US20180092961A1 (en) 2018-04-05
US20140308289A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
US11458187B2 (en) Extracellular histones as biomarkers for prognosis and molecular targets for therapy
EP1755642B1 (en) Annexin v for preventing plaque rupture
CN103068845A (zh) 用于治疗间质性肺病的因子xii抑制剂
US10646556B2 (en) Methods for treatment of and prophylaxis against inflammatory disorders
JP2017186340A (ja) 血液凝固促進に使用するための化合物
AU2015229251A1 (en) Compositions and methods for preventing or treating chronic lung allograft dysfunction and idiopathic pulmonary fibrosis
EP3182983B1 (en) Antibodies to polyphosphate decrease clot formation, decrease inflammation, and improve survival
US8173595B2 (en) Methods and compositions for the inhibition of thrombus formation
US20090181057A1 (en) Methods and Compositions for the Inhibition of Thrombus Formation
WO2015085311A1 (en) Compositions and methods of treating thrombosis
US20220002363A1 (en) Compositions and methods for treating pulmonary disease
JP2012224549A (ja) 抗凝固薬及びその用途
KR20160143820A (ko) 출혈의 예방 및 치료를 위한 반감기 연장 인자 ｆｖｉｉａ 단백질 및 이의 투약 용법
JP2009502849A (ja) 血栓症及び癌の治療、及び／又は予防のためのａｃｒｐ３０の使用
Wong Structure and Functions of Canine Protein C
WO2004030695A1 (en) Treatment of vascular diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)